A. Overview of neurovascular unit showing perivascular innervation, astroglia projecting end feet to the pial surface, NMDA receptor neurons (lower cells), and interneurons (dark cells). NMDA receptor containing neurons may also contain neuronal NOS (nNOS) or alternatively activate nNOS containing interneurons. B. The major dilator influences on pial arteries and arterioles. The major dilator agents are calcitonin gene-related peptide (CGRP) release by trigeminal afferents and acetylcholine (Ach) released from perivascular nerves and nitric oxide (NO) derived from neural sources (perivascular nerves or parenchyma). In each species studied the relative importance of each type of vasoactive influence appears to vary. In addition, the pathophysiological and pharmacological status of the animal would affect the relative importance of each component. C. The major vasoactive influences on parenchymal arterioles. In addition to neurotransmitters such as CGRP from trigeminal afferents and neuronally-derived NO promoting dilation, vascular and perivascular prostaglandins will reduce constriction in parenchymal as well as pial resistance vessels (not shown) during CSD. In addition, parenchymal-derived prostaglandins will promote vasoconstriction during the post CSD period. Upstream propagation of arterial dilation may involve perivascular nerves or other vascular components as well as well as substances released from glial end feet, although flow dependent dilation in the “classical” case probably does not occur for reasons stated in the text. Abbreviations: EC, endothelial cell; VSM, vascular smooth muscle cell; NMDAR, NMDA receptor; Trig. A.,Trigeminal afferent; Parasymp. N., Parasympathetic nerve.